Literature DB >> 20306266

Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea.

Clovis A Silva1, Maria E J Deen, Marilia V Febrônio, Sheila K Oliveira, Maria T Terreri, Silvana B Sacchetti, Flavio R Sztajnbok, Roberto Marini, Maria V Quintero, Blanca E Bica, Rosa M Pereira, Eloisa Bonfá, Virginia P Ferriani, Teresa C Robazzi, Claudia S Magalhães, Maria O Hilário.   

Abstract

To identify the underlying mechanism of amenorrhea in juvenile systemic lupus erythematosus (JSLE) patients, thirty-five (11.7%) JSLE patients with current or previous amenorrhea were consecutively selected among the 298 post-menarche patients followed in 12 Brazilian pediatric rheumatology centers. Pituitary gonadotrophins [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)] and estradiol were evaluated in 32/35 patients, and prolactin and total testosterone in 29/35 patients. Patient's medical records were carefully reviewed according to demographic, clinical and therapeutic findings. The mean duration of amenorrhea was 7.2 ± 3.6 months. Low FSH or LH was observed in 7/32 (22%) JSLE patients and normal FSH or LH in 25 (78%). Remarkably, low levels of FSH or LH were associated with higher frequency of current amenorrhea (57% vs. 0%, P = 0.001), higher median disease activity (SLEDAI) and damage (SLICC/ACR-DI) (18 vs. 4, P = 0.011; 2 vs. 0, P = 0.037, respectively) and higher median current dose of prednisone (60 vs. 10 mg/day, P = 0.0001) compared to normal FSH or LH JSLE patients. None of them had decreased ovarian reserve and premature ovarian failure. Six of 29 (21%) patients had high levels of prolactin, and none had current amenorrhea. No correlations were observed between levels of prolactin and SLEDAI, and levels of prolactin and SLICC/ACR-DI scores (Spearman's coefficient). We have identified that amenorrhea in JSLE is associated with high dose of corticosteroids indicated for active disease due to hypothalamic-pituitary-ovary axis suppression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306266     DOI: 10.1007/s00296-010-1389-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.

Authors:  Hermine I Brunner; Earl D Silverman; Theresa To; Claire Bombardier; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2002-02

Review 3.  Treatment of lupus nephritis in children.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

4.  Incidence of ovulation in the years after the menarche.

Authors:  M G Metcalf; D S Skidmore; G F Lowry; J A Mackenzie
Journal:  J Endocrinol       Date:  1983-05       Impact factor: 4.286

5.  Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study.

Authors:  Angelo Ravelli; Carolina Duarte-Salazar; Silvia Buratti; Andreas Reiff; Bram Bernstein; Maria Rocio Maldonado-Velazquez; Rosalia Beristain-Manterola; Nobuaki Maeno; Syuji Takei; Valeria Gerloni; Charles H Spencer; Polyxeni Pratsidou-Gertsi; Nicolino Ruperto; Angela Pistorio; Alberto Martini
Journal:  Arthritis Rheum       Date:  2003-08-15

6.  Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.

Authors:  D T Boumpas; H A Austin; E M Vaughan; C H Yarboro; J H Klippel; J E Balow
Journal:  Ann Intern Med       Date:  1993-09-01       Impact factor: 25.391

7.  Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus.

Authors:  C L Wang; F Wang; J J Bosco
Journal:  Lupus       Date:  1995-02       Impact factor: 2.911

8.  Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids.

Authors:  M Saketos; N Sharma; N F Santoro
Journal:  Biol Reprod       Date:  1993-12       Impact factor: 4.285

9.  Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients.

Authors:  N N Fatnoon; S M Azarisman; D Zainal
Journal:  Singapore Med J       Date:  2008-05       Impact factor: 1.858

Review 10.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03
View more
  6 in total

Review 1.  Taxonomy for systemic lupus erythematosus with onset before adulthood.

Authors:  Clovis A Silva; Tadej Avcin; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

2.  [Pregnancy outcome in a woman with premature ovarian insufficiency complicated by systemic lupus erythematosus during pregnancy: a case report].

Authors:  Wan-le Chen; Yu-Dong Liu; Xue-Lan Li; Shu-Xian Feng; Xing-Yu Zhou; Wei-Xu Ma; Ying Li; De-Sheng Ye; Xin Chen; Shi-Ling Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-12-20

3.  Prolactin has a pathogenic role in systemic lupus erythematosus.

Authors:  Luis J Jara; Gabriela Medina; Miguel A Saavedra; Olga Vera-Lastra; Honorio Torres-Aguilar; Carmen Navarro; Monica Vazquez Del Mercado; Luis R Espinoza
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

4.  Penile alterations with severe sperm abnormalities in antiphospholipid syndrome associated with systemic lupus erythematosus.

Authors:  Carlos Nobre Rabelo-Júnior; Eloisa Bonfá; Jozélio F Carvalho; Marcello Cocuzza; Osmar Saito; Carmita H Abdo; Clovis A Silva
Journal:  Clin Rheumatol       Date:  2012-09-11       Impact factor: 2.980

Review 5.  Evolutionary medicine and chronic inflammatory state--known and new concepts in pathophysiology.

Authors:  Rainer H Straub
Journal:  J Mol Med (Berl)       Date:  2012-01-22       Impact factor: 4.599

Review 6.  Chronic inflammatory systemic diseases: An evolutionary trade-off between acutely beneficial but chronically harmful programs.

Authors:  Rainer H Straub; Carsten Schradin
Journal:  Evol Med Public Health       Date:  2016-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.